NASDAQ:ARYD ARYA Sciences Acquisition Corp IV (ARYD) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free ARYD Stock Alerts $11.35 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$11.35▼$11.3950-Day Range$11.18▼$11.3552-Week Range$10.40▼$11.39Volume1,542 shsAverage Volume13,960 shsMarket Capitalization$85.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial Media Get ARYA Sciences Acquisition Corp IV alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About ARYA Sciences Acquisition Corp IV Stock (NASDAQ:ARYD)Arya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.Read More ARYD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARYD Stock News HeadlinesFebruary 14, 2024 | msn.comAdagio Medical to go public in $113M deal with SPAC ARYA SciencesFebruary 14, 2024 | finance.yahoo.comAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.February 14, 2024 | prnewswire.comAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesApril 7, 2023 | marketwatch.com8-K: ARYA Sciences Acquisition Corp IVFebruary 24, 2022 | benzinga.comARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus' Gene Therapy Business Due to Market ConditionsNovember 30, 2021 | finance.yahoo.comMoore Kuehn Encourages KOR, DISCA, FTSI, and ARYD Investors to Contact Law FirmNovember 9, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of EJF, HTPA, ARYD, and ADER MergersApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.October 6, 2021 | finance.yahoo.comMoore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law FirmOctober 1, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ARYA Sciences Acquisition Corp. IV MergerSeptember 30, 2021 | entrepreneur.comAmcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYASeptember 30, 2021 | msn.comAmicus Therapeutics Stock Rises; Sells Unit Stake in SPAC DealSeptember 30, 2021 | finance.yahoo.comAmicus stock is up 5%, the day after announcing plans to sell its gene therapy businessSeptember 29, 2021 | finance.yahoo.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD)September 29, 2021 | feeds.benzinga.comPerceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy BusinessSeptember 29, 2021 | apnews.comAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a ...September 29, 2021 | finance.yahoo.comAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”See More Headlines Receive ARYD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARYA Sciences Acquisition Corp IV and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:ARYD CUSIPN/A CIK1838821 Webwww.perceptivelife.com Phone212-284-2300FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.83% Return on Assets-5.41% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.49) per share Price / Book-3.25Miscellaneous Outstanding Shares7,540,000Free Float3,508,000Market Cap$85.58 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Adam Leo Stone (Age 44)CEO & Director Mr. Michael Seth Altman CFA (Age 42)CFO & Director Mr. Konstantin Poukalov (Age 40)Chief Business Officer Key CompetitorsFuture Health ESGNASDAQ:FHLTCascadia AcquisitionNASDAQ:CCAIAlpha Healthcare Acquisition Corp. IIINASDAQ:ALPAPrenetics GlobalNASDAQ:PREReviva PharmaceuticalsNASDAQ:RVPHView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 18,793 shares on 2/26/2024Ownership: 0.237%Glazer Capital LLCSold 3,057 shares on 2/15/2024Ownership: 6.234%Berkley W R CorpBought 36,888 shares on 2/15/2024Ownership: 2.382%Hsbc Holdings PLCBought 149,910 shares on 2/12/2024Ownership: 1.890%Cowen AND Company LLCSold 11,705 shares on 2/8/2024Ownership: 2.281%View All Institutional Transactions ARYD Stock Analysis - Frequently Asked Questions How have ARYD shares performed in 2024? ARYA Sciences Acquisition Corp IV's stock was trading at $10.90 on January 1st, 2024. Since then, ARYD shares have increased by 4.1% and is now trading at $11.35. View the best growth stocks for 2024 here. Are investors shorting ARYA Sciences Acquisition Corp IV? ARYA Sciences Acquisition Corp IV saw a decrease in short interest in March. As of March 31st, there was short interest totaling 100 shares, a decrease of 87.5% from the March 15th total of 800 shares. Based on an average daily volume of 39,800 shares, the days-to-cover ratio is currently 0.0 days. View ARYA Sciences Acquisition Corp IV's Short Interest. When did ARYA Sciences Acquisition Corp IV IPO? ARYA Sciences Acquisition Corp IV (ARYD) raised $130 million in an IPO on Friday, February 26th 2021. The company issued 13,000,000 shares at a price of $10.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO. How do I buy shares of ARYA Sciences Acquisition Corp IV? Shares of ARYD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARYD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARYA Sciences Acquisition Corp IV Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
